CompletedPhase 2

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

United States72 participantsStarted 2021-10-22

Plain-language summary

This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior therapy.

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Cohort A (AVPCa) - Aggressive variant prostate cancer
✓. Cohort B or C (HRD) - Homologous recombination deficient (HRD) tumor
✓. Cohort D (MSI-H/MMRD) - Microsatellite instability-high (MSI-H) or mismatch repair deficient (MMRD) tumors (MSI-H/MMRD) or TMB-H (≥ 10 mut/Mb)
✓. Cohort E (No Targetable Mutations)

What they're measuring

Incidence of treatment-emergent adverse events (safety and tolerability of vudalimab)

Timeframe: 8 weeks

Trial details

NCT IDNCT05005728

SponsorXencor, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-06-10

View on ClinicalTrials.gov More Metastatic Castration-Resistant Prostate Cancer trials